In a clinical trial, the BRMS1 drug inhibited metastasis by suppressing NF-kB activity and IL-6 expression, while inducing the expression of ING4, pointing to its possible role as a tumor suppressor in melanomas [71]. Here, ING4 is linked to melanoma.